Appili Therapeutics Inc.

News & Events

Press Releases

In The Media

1. Appili Therapeutics Reports Fiscal Year 2025 Financial and Operational Results

   GlobeNewswire JUN 25, 2025 6:04 PM EDT
   LIKMEZ™ (ATI-1501) for Metronidazole Oral Suspension 500mg/5mL re-launched and commercial ...
   READ ARTICLE

2. Appili Therapeutics Announces Formal Termination of Arrangement Agreement with Aditxt Inc.

   GlobeNewswire MAY 30, 2025 7:17 AM EDT
   NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES...
   READ ARTICLE

3. Appili Therapeutics Provides Update on Arrangement with Aditxt, Inc.

   GlobeNewswire MAY 19, 2025 8:00 AM EDT
   NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES...
   READ ARTICLE

4. Appili Therapeutics and Colleagues Publish Manuscript on the Prevention and Emergency Response to Tularemia

   GlobeNewswire MAY 1, 2025 7:34 AM EDT
   HALIFAX, Nova Scotia, May 01, 2025 (GLOBE NEWSWIRE) -- Appili Therapeutics Inc. (TSX:APLI; OTCPin...
   READ ARTICLE

5. Appili Therapeutics Announces New Patents Granted for Commercial Stage Asset LIKMEZ®(TM)

   GlobeNewswire APR 28, 2025 7:41 AM EDT
   New patents provide additional composition of matter and methods of use claims, strengthening the...
   READ ARTICLE

6. Appili President and CEO, Don Cilla to Join Aditxt CEO, Amro Albanna for Aditxt Weekly Update on April 4, 2025

   GlobeNewswire APR 2, 2025 8:17 AM EDT
   Event exploring the escalating threat of emerging infectious diseases Discussion covering...
   READ ARTICLE

7. Appili President and CEO, Don Cilla Will Join Aditxt Co-founder and CEO, Amro Albanna, at the Aditxt Weekly Update on April 4, 2025

   Business Wire APR 2, 2025 8:15 AM EDT
   Event exploring the increasing risk of emerging infectious diseases Update on Appili tran...
   READ ARTICLE

8. Upcoming Aditxt Weekly Update to Highlight Pearsanta's Acquisition of the Adductomics-Based CaSe Platform and its Potential for Early Cancer Detection

   Business Wire MAR 28, 2025 8:15 AM EDT
   The event will begin today at 11:30 a.m. ET Event to feature Dr. Shahrokh Shabahang, Chie...
   READ ARTICLE

9. Aditxt Subsidiary Pearsanta Completes the Acquisition of Proprietary Adductomics Technology to Develop and Advance the Platform Toward Clinical and Commercial Applications for Monitoring Early Signs of Increased Cancer Risk

   Business Wire MAR 24, 2025 8:15 AM EDT
   Acquisition is key to Pearsanta’s mission of addressing cancer through early detection and...
   READ ARTICLE

10. Appili Therapeutics Announces Submission of U.S. Federal Government Funding Proposals and Provides Corporate and Aditxt Transaction Update

    GlobeNewswire MAR 18, 2025 7:22 AM EDT
    Four new funding proposals, totalling US$117.5 million, have been submitted for review Modi...
    READ ARTICLE